|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Eptifibatide#Adult Indications and Dosage]] |
| {{Eptifibatide}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Dosage and Administration==
| |
| Before infusion of INTEGRILIN, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing [[PCI]], the activated clotting time ([[ACT]]) should also be measured.
| |
| | |
| The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT.
| |
| | |
| ===Dosage in Acute Coronary Syndrome (ACS)===
| |
| {|
| |
| |-
| |
| |[[File:Eptifibatide01.jpg|thumb|800px]]
| |
| |-
| |
| |}
| |
| | |
| INTEGRILIN should be given concomitantly with [[heparin]] dosed to achieve the following parameters:
| |
| | |
| During Medical Management: Target aPTT 50 to 70 seconds
| |
| *If weight greater than or equal to 70 kg, 5000-unit bolus followed by infusion of 1000 units/h.
| |
| *If weight less than 70 kg, 60-units/kg bolus followed by infusion of 12 units/kg/h.
| |
| | |
| During PCI: Target ACT 200 to 300 seconds
| |
| *If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds.
| |
| *[[Heparin]] infusion after the PCI is discouraged.
| |
| | |
| ===Dosage in Percutaneous Coronary Intervention (PCI)===
| |
| | |
| {|
| |
| |-
| |
| |[[File:Eptifibatide02.jpg|thumb|800px]]
| |
| |-
| |
| |}
| |
| | |
| Patients requiring thrombolytic therapy should discontinue INTEGRILIN.
| |
| | |
| ===Important Administration Instructions===
| |
| | |
| 1.Inspect INTEGRILIN for particulate matter and discoloration prior to administration, whenever solution and container permit.
| |
| 2.May administer INTEGRILIN in the same intravenous line as [[alteplase]], [[atropine]], [[dobutamine]], [[heparin]], [[lidocaine]], [[meperidine]], [[metoprolol]], [[midazolam]], [[morphine]], [[nitroglycerin]], or [[verapamil]]. Do not administer INTEGRILIN through the same intravenous line as [[furosemide]].
| |
| 3.May administer INTEGRILIN in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride.
| |
| 4.Withdraw the bolus dose(s) of INTEGRILIN from the 10-mL vial into a syringe. Administer the bolus dose(s) by IV push.
| |
| 5.Immediately following the bolus dose administration, initiate a continuous infusion of INTEGRILIN. When using an intravenous infusion pump, administer INTEGRILIN undiluted directly from the 100-mL vial. Spike the 100-mL vial with a vented infusion set. Center the spike within the circle on the stopper top.
| |
| 6.Discard any unused portion left in the vial.
| |
| | |
| Administer INTEGRILIN by volume according to patient weight (see Table 1).
| |
| | |
| {|
| |
| |-
| |
| |[[File:E.jpg|thumb|800px]]
| |
| | |
| |-
| |
| |}
| |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INTEGRILIN (EPTIFIBATIDE) INJECTION, SOLUTION [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ad82e30-50d8-450c-8a2a-b4b507ed1ce2 | publisher = | date = | accessdate = 5 February 2014 }}</ref>
| |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antiplatelet drugs]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |